DAPOFORCE 30

What is DAPOFORCE 30?

DAPOFORCE 30 is a specialized pharmaceutical product developed for the correction of premature ejaculation in men. The medication is produced in the form of film-coated tablets, which ensures accurate dosing and convenient oral administration. The pharmacological group of the drug is short-acting selective serotonin reuptake inhibitors, which selectively target the neurochemical mechanisms regulating the ejaculatory reflex. The manufacturer of DAPOFORCE 30 is the Indian pharmaceutical company Healing Pharma, which specializes in the production of high-quality generic drugs with proven bioequivalence to original medications. The drug belongs to the category of men's health products and is dispensed by prescription.

The active component of DAPOFORCE 30 is dapoxetine hydrochloride at a dosage of 30 mg, which corresponds to the International Nonproprietary Name Dapoxetine. This substance was specifically developed for the treatment of premature ejaculation and differs from classic SSRI antidepressants by its rapid onset of action and short elimination half-life. These specific pharmacokinetic characteristics allow the drug to be used on an as-needed basis, without the necessity of long-term accumulation in the body. The therapeutic effect of DAPOFORCE 30 is achieved by increasing serotonin concentration in the synaptic cleft, which leads to the inhibition of spinal reflexes responsible for ejaculation. The drug does not affect libido and does not impair spermatogenesis, which has been confirmed by clinical studies.

DAPOFORCE 30 is supplied in blisters that protect the tablets from moisture and light, maintaining the stability of the active substance throughout its shelf life. Each tablet contains a precisely calibrated amount of dapoxetine, guaranteeing predictability of the therapeutic response and minimizing the risk of overdose. The medication has been registered in accordance with international GMP quality standards, confirming that manufacturing processes comply with strict pharmaceutical requirements. Healing Pharma positions DAPOFORCE 30 as an affordable alternative to original dapoxetine with an identical efficacy and safety profile. The use of this drug allows men to restore confidence in their own abilities and improve the quality of their intimate life.

Why is DAPOFORCE 30 prescribed?

The primary indication for the use of DAPOFORCE 30 is premature ejaculation — a condition in which ejaculation occurs within one minute after the start of sexual intercourse, or even before it begins. This disorder is among the most common sexual dysfunctions in men aged 18 to 64 and significantly reduces the quality of life, causing psychological discomfort and strain in relationships. The medication helps to increase the intravaginal ejaculation latency time by an average of two to three times compared to baseline values. DAPOFORCE 30 is also prescribed to patients whose premature ejaculation is accompanied by a pronounced sense of loss of control over the process of ejaculation. The therapeutic effect is observed right after the first dose, which favorably distinguishes the drug from products that require cumulative dosing.

DAPOFORCE 30 is effective in cases of primary premature ejaculation, which is present from the onset of sexual life and has a predominantly constitutional or neurobiological nature. The medication is also used for the secondary form of the disorder, which develops against the background of chronic stress, anxiety states, depressive episodes, or somatic diseases of the genitourinary system. In such cases, dapoxetine acts on the central mechanisms of ejaculation regulation, eliminating excessive excitability of the reflex arc. It is important to understand that DAPOFORCE 30 is not intended to treat erectile dysfunction, although it may indirectly improve erection by reducing anxiety associated with performance fear. Patients with combined disorders may be recommended combination therapy under medical supervision.

A separate category of patients prescribed DAPOFORCE 30 includes men with situational premature ejaculation, which occurs episodically due to overwork, prolonged abstinence, or excessive psycho-emotional excitement. In such cases, the drug is used on an as-needed basis, without the requirement for continuous administration, thereby reducing the drug load on the body. Clinical studies have confirmed that dapoxetine at a dose of 30 mg significantly increases control over ejaculation and enhances satisfaction with sexual intercourse for both partners. The drug also helps reduce psychological distress associated with premature ejaculation, which positively affects the patient's overall emotional state. The prescription of DAPOFORCE 30 should be made by a physician after ruling out organic causes of the disorder, such as prostatitis, urethritis, or neurological diseases.

Composition and active components of DAPOFORCE 30

The active substance of DAPOFORCE 30 is dapoxetine hydrochloride in an amount of 30 mg per single tablet. Dapoxetine belongs to the class of selective serotonin reuptake inhibitors; however, it possesses a unique pharmacokinetics that sets it apart from antidepressants of this group. After oral administration, the drug is rapidly absorbed in the gastrointestinal tract, reaching peak plasma concentration within one to two hours. The elimination half-life of dapoxetine is approximately 19 hours, ensuring a prompt completion of action and minimizing the risk of accumulation during episodic use. The mechanism of action involves blocking the reuptake of serotonin in central nervous system neurons, leading to an increase in its concentration in the synaptic cleft and enhancing the inhibitory influence on spinal ejaculation centers.

Excipients of DAPOFORCE 30 include lactose monohydrate, which serves as a filler and provides the necessary weight of the tablet, microcrystalline cellulose to impart structural strength, and croscarmellose sodium, which promotes rapid disintegration of the tablet in the stomach. The coating consists of hypromellose, titanium dioxide, and colorants, which protect the active substance from premature degradation and facilitate swallowing. Additionally, magnesium stearate may be used as a lubricant and silicon dioxide to improve the flow properties of the powder mass during manufacturing. All inactive ingredients are pharmacologically inert and do not affect the therapeutic action of the drug; however, patients with lactose intolerance should take its presence in the formulation into account.

The pharmacodynamics of DAPOFORCE 30 is realized through the modulation of the serotonergic system, which plays a key role in regulating the ejaculatory reflex. Increasing serotonin levels in synapses leads to the activation of postsynaptic receptors that inhibit the transmission of excitation from peripheral nerve endings to spinal centers responsible for ejaculation. This allows a man to consciously control the moment of orgasm and prolong sexual intercourse. It is important to note that dapoxetine does not affect the dopaminergic system and therefore does not cause addiction, euphoria, or mood changes characteristic of psychostimulants. The drug also does not disrupt hormonal balance, does not lower testosterone levels, and does not affect male fertility.

Dosage of DAPOFORCE 30

The recommended starting dose of DAPOFORCE 30 for adult men is 30 mg (one tablet) taken one to three hours before planned sexual activity. The drug is intended for situational use and should not be taken daily in the absence of sexual activity. The maximum dosing frequency must not exceed one tablet per day, as exceeding the dose increases the risk of side effects without a proportional increase in therapeutic effect. If the effect after the initial 30 mg dose proves insufficient, the physician may consider increasing the dose to 60 mg; however, such a decision is made exclusively after assessing individual tolerance to the drug. Increasing the dosage independently is strictly discouraged.

The duration of DAPOFORCE 30 therapy course is determined individually depending on the nature of the disorder and the patient's response to treatment. For most men, episodic use of the drug before sexual intercourse is sufficient, avoiding a constant pharmacological burden. In cases of chronic premature ejaculation with a pronounced psychological component, a doctor may recommend regular use for several weeks to consolidate positive experiences and build confidence. Once stable control over ejaculation is achieved, the frequency of administration is gradually reduced to the minimum effective level. Patients with mild hepatic impairment do not require dose adjustment, but caution should be exercised in cases of moderate impairment.

For elderly patients over 65 years of age, there are no special recommendations for modifying the dosage of DAPOFORCE 30; however, possible metabolic slowing and increased sensitivity to the drug should be taken into account. Men with light to moderate renal impairment do not require dose adjustment, but in severe renal impairment, the use of the drug is not recommended due to insufficient safety data. It is important to remember that DAPOFORCE 30 is not intended for use in women or individuals under 18 years of age. Prior to starting therapy, an examination must be undergone to exclude contraindications and evaluate overall health status.

How to take DAPOFORCE 30 correctly?

DAPOFORCE 30 is taken orally, swallowing the tablet whole with a sufficient amount of water, without chewing or crushing it. The optimal time of administration is one to three hours prior to expected sexual intercourse, as the concentration of the active substance in the blood reaches its therapeutic level during this period. The drug can be taken regardless of food intake; however, fatty meals may delay the absorption of dapoxetine and postpone the onset of action. To achieve a predictable result, it is recommended to adhere to identical conditions of administration — for instance, always taking the tablet on an empty stomach or always after a light snack. Alcohol should be excluded during the use of DAPOFORCE 30, as ethanol enhances the sedative effect of the drug and increases the risk of orthostatic hypotension.

If a dose of DAPOFORCE 30 was missed, one should not double the dose next time — it is sufficient to take one tablet before the next planned sexual act. The drug is not intended for continuous daily use, so the concept of a "missed dose" is conditional and applies only to cases where the patient forgot to take a tablet before planned intimacy. In such a situation, the medication can be taken later if at least one hour remains before sexual intercourse, or postponed to the next time. It is important not to exceed the maximum daily dose of 30 mg without a doctor's prescription. Patients starting therapy for the first time are advised to perform a trial intake in a calm setting to evaluate their individual body reaction.

When taking DAPOFORCE 30, caution should be exercised while driving vehicles or operating machinery, as the medication may cause dizziness, drowsiness, or decreased concentration. This is especially true during the first few hours after administration when the concentration of dapoxetine in the blood is at its peak. Patients with labile blood pressure are recommended to monitor their readings during therapy, as episodes of orthostatic hypotension may occur upon sudden changes in body position. In the event of severe dizziness, fainting, or other alarming symptoms, it is necessary to stop taking the drug and consult a doctor. The individual reaction of the body to DAPOFORCE 30 may vary depending on age, health status, and concomitant therapy.

Side effects of DAPOFORCE 30

The most common side effects of DAPOFORCE 30 are nausea, dizziness, and headache, which occur mainly during the first hours after administration and usually resolve spontaneously. These symptoms are related to the pharmacological action of dapoxetine on serotonin receptors and are most frequently observed at the beginning of therapy as the body adapts to the drug. To reduce nausea, it is recommended to take the tablet after a light snack and avoid fatty foods. Dizziness may worsen when standing up quickly, so patients should avoid rapid changes in body position for several hours after taking the dose. Most patients note a reduction in the severity of side effects with repeated use of the medication.

Uncommon adverse reactions of DAPOFORCE 30 include diarrhea, insomnia, increased sweating, anxiety, and decreased libido. Some patients may experience cardiovascular disturbances, including palpitations, hot flashes, or a slight increase in blood pressure. Rare side effects include syncopal states, marked bradycardia, and allergic reactions such as skin rash, itching, or hives. In isolated cases, the development of serotonin syndrome has been reported with concurrent use of other drugs that raise serotonin levels. The appearance of any unusual symptoms requires consultation with a doctor to evaluate the appropriateness of continuing therapy.

Special attention is required for patients prone to orthostatic hypotension, as DAPOFORCE 30 can trigger a sharp drop in blood pressure when changing body position. In case of pre-fainting sensations, severe dizziness, or loss of consciousness, administration must be stopped immediately and medical help sought. Patients with depressive disorders should remain under medical supervision, as dapoxetine can affect emotional state. It is important to remember that the body's individual response to the drug can be unpredictable, so the first dose is recommended to be taken in a safe environment. Before starting DAPOFORCE 30 therapy, be sure to consult a physician regarding possible risks and expected benefits.

Contraindications of DAPOFORCE 30

Absolute contraindications to the use of DAPOFORCE 30 are hypersensitivity to dapoxetine or any excipient component of the drug. The medication is forbidden for patients with severe liver diseases, as the metabolism of dapoxetine occurs primarily in this organ, and impaired liver function can lead to toxic accumulation of the active substance. DAPOFORCE 30 is not prescribed to men with clinically significant cardiovascular diseases, such as unstable angina, recent myocardial infarction, severe arrhythmias, or uncontrolled arterial hypertension. A history of syncopal states is also a contraindication due to the risk of recurrent episodes of loss of consciousness while taking the drug.

DAPOFORCE 30 is not used in patients taking monoamine oxidase inhibitors, as well as within 14 days after their discontinuation, because such a combination can provoke life-threatening serotonin syndrome. Concurrent use with other selective serotonin reuptake inhibitors, tricyclic antidepressants, and lithium preparations is contraindicated. The drug is not prescribed to men with severe psychiatric disorders, such as bipolar affective disorder or schizophrenia, due to the risk of exacerbating symptoms. In patients with a history of epilepsy, DAPOFORCE 30 should be used with caution, as dapoxetine may lower the seizure threshold. The presence of severe renal failure is also a contraindication to the use of the drug.

DAPOFORCE 30 is strictly not intended for use in women, children, and adolescents under 18 years of age. The drug has not been studied in these populations, so data regarding safety and efficacy are lacking. In elderly men over 65 years of age, the drug may be prescribed only after a careful assessment of the benefit-risk ratio, taking into account concomitant diseases and the use of other medicines. For patients with depressive disorders accompanied by suicidal thoughts, DAPOFORCE 30 is not recommended due to potential effects on the psycho-emotional state. Before initiating therapy, be sure to inform your doctor about all existing conditions and medications you are taking to avoid dangerous interactions.

Interaction of DAPOFORCE 30 with other drugs and alcohol

DAPOFORCE 30 enters into clinically significant interactions with drugs affecting the serotonin system, so concurrent use with SSRI, SNRI antidepressants, tricyclic antidepressants, and MAO inhibitors is strictly prohibited. Such a combination can lead to the development of serotonin syndrome, manifested by agitation, confusion, fever, tremor, and seizures. Drugs that inhibit the CYP3A4 enzyme, such as ketoconazole, itraconazole, ritonavir, and clarithromycin, can increase the concentration of dapoxetine in the blood, elevating the risk of side effects. Inducers of this enzyme, conversely, reduce the efficacy of DAPOFORCE 30. Patients taking anticoagulants should exercise caution due to the potential effect of dapoxetine on platelet aggregation.

Concomitant consumption of alcohol with DAPOFORCE 30 is not recommended, as ethanol enhances the sedative effect of the drug, increases the risk of dizziness, orthostatic hypotension, and impaired motor coordination. Alcohol can also reduce the therapeutic efficacy of dapoxetine because it affects the central nervous system and alters the neurochemical processes targeted by the drug. During DAPOFORCE 30 therapy, one should refrain from driving vehicles and working with dangerous machinery for at least six hours after taking the dose, as the drug can cause drowsiness and reduced reaction speed. Individual sensitivity to the drug may vary, so an initial assessment of the effect on psychomotor functions should be conducted in safe conditions.

Where to buy DAPOFORCE 30 in Ukraine

DAPOFORCE 30 is available in pharmacy chains across Ukraine by prescription, which guarantees controlled use of the drug and minimizes the risk of self-medication. The product can be purchased both in physical brick-and-mortar pharmacies and via licensed online services that deliver medications upon presentation of a prescription. The price of DAPOFORCE 30 is more affordable compared to original dapoxetine, making therapy cost-effective for patients requiring long-term use. Before purchasing, it is recommended to verify the seller's license and the integrity of the packaging to avoid buying counterfeit products.

DAPOFORCE 30 must be stored in its original packaging at a temperature not exceeding 25 degrees Celsius, in a dry place protected from light and out of reach of children. The shelf life of the drug is usually two to three years from the date of manufacture, after which use is forbidden. For detailed information regarding the availability of the drug in a specific region of Ukraine, it is recommended to contact information services of pharmacy networks or use official online drug search platforms. Remember that self-treatment can be hazardous to your health, so before starting DAPOFORCE 30 therapy, be sure to consult a qualified physician to determine the optimal treatment regimen and exclude contraindications.